Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis - Assessment in chronic hemodialysis patients

64Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Background: Monocyte chemoattractant protein-1 (MCP-1), a potent chemoattractant for monocytes, plays an important role in the earliest events of atherogenesis. However, direct evidence of the effects of MCP-1 on atherosclerosis in chronic hemodialysis (HD) patients has not been reported. Methods and Results: The serum MCP-1 concentrations and the intimal-medial thickness (IMT) in the carotid arteries were measured in 42 non-diabetic chronic HD patients and 20 age-matched controls. The expression of MCP-1 was examined immunohistochemically in radial arterial tissues obtained from the HD patients. IMT and the serum concentration of MCP-1 in the HD patients were both significantly greater than in controls. Multiple regression analysis revealed that the serum concentration of MCP-1 was an independent factor influencing IMT. Tissue immunostaining showed that MCP-1 is expressed in both endothelial and smooth muscle cells and that its level of expression correlates with the serum concentration of MCP-1. Conclusions: An increase in MCP-1 may be an important factor in the progression of atherosclerosis in non-diabetic HD patients.

Author supplied keywords

Cite

CITATION STYLE

APA

Kusano, K. F., Nakamura, K., Kusano, H., Nishii, N., Banba, K., Ikeda, T., … Ohe, T. (2004). Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis - Assessment in chronic hemodialysis patients. Circulation Journal, 68(7), 671–676. https://doi.org/10.1253/circj.68.671

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free